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immune globalin (MG).
A nnmber of small trials and a few reports suggest that M G is safe and effective in the treatment of patients with autoimmune neuropathies, inflammatory myopathies, and myasthenia gravis unrespoosive to conventional therapies. We will present current experience with M G in the abovementioned autoimmune w~romascalru d h a e s , and we will stress the need for long-term controlled studies. The possible immunomodulatory action of M G in these con-sumed dysimmune or autoimmune pathogemesis and indude hhnmamry neuropathies, i-matory myopathies, and autoimmune neummuscular junction def-
The most acmpted treabmentforallthesedisorders,withtheexctptionofGBS,is coxticatemid therapy given in high doses and for long periods of time in an attempt to induce remissions or halt the progression of the disease (4-9). Other immunosuppressive agents, which include azathioprine, cyclophosphamide, cyclosporine, and methotrexate, have also been used, with only limited success, however (6, 9, 10) . The use of these drugs, including steroids, is restricted not only by their limited effectiveness but also by the significant side effects that accompany long-term therapy. PE has also been used in these disordexs and is beneficial in GBS (1 1, 12) and MG (7, 10) but is not as helpful in CIDP (13). the course of the disease.
Plasmapheresis is ineffective in PM/DM (5)
.
Passive transfer experiments
A number of possible mechanisms have been proposed re-
Hyperactive thymus gland
cently (27, 28) that could explain the mode of action of IVIG.
Experimental allergic MG
These mechanisms are summarized in asymptomatic family members of MG patients is controversial, but one questions how prevalent these antibodies are in the The role of the antibodies to AChR in the pathogenesis of MG general Population (38). Another mechanism proposed for the is well established. The antibody first binds to one or more action of IVIG is FC receptor blockade. The basis for this proposal epitopes of the A C~R ; this leads to a number of possible events is the observation that a beneficial response was obtained from that in turn cause destruction or enhanced degradation of AChR. infusions of 7s but not 5s IVIG (17,241. A decrease in the available number of receptors causes failure of the neuromuscular transmission and results in muscle weakness.
INFLAMMATORY NEUROPATHIES
Serum IgG from myasthenic patients can transmit the disease in mice. The animal model, EAMG, has greatly enhanced our A number of recent studies have provided insight into the understanding of the immunopathogenesis of MG. In EAMG, pathogenesis of inflammatory dem~elinating ~ol~neuro~athies accelerated degradation of the receptor occurs as a result of cross- (6, 8, 9, (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) . The immuno~athogenesis of GBS is reviewed linking adjacent molecules by bivalent IgG in the absence of by Rostami (this issue). The principal proposed mechanisms are complement. The role of cytotoxic T cells is unclear; however, summarized in Tables 4 and 5. The electro~h~siologic principle T cells appear to play an immunoregulatory role in the disease. of weakness in GBS or CIDP, at least early in the disease, is the Moreover, the thymus gland is hyperplastic or thymomatous, conduction block produced when a portion of the axon fails to hypersecretes thymic hormones, and contains A C~R in its myoid transmit impulses in a segment where myelin has been destroyed cells. Furthermore, thymectomy facilitates the patient's improve-0' rendered nonfunctional. Antibodies or autoaggressive CYtoment or causes complete remission.
toxic T cells block myelin components, or saltatory conduction Treatment of MG with immune globulin was first reported in at the nodes of Ranvier may be responsible for this phenomenon. 1984, when five patients were treated with highdose IVIG over a 5 4 period and all had a favorable response (15). Since the Table 3 . Proposed mechanisms of action of IVIG in original report, approximately 9 1 patients with MG have received autoimmune neuromuscular diseases IVIG as part of small, uncontrolled clinical trials or case reports 1 . Immunomodulation by Fc receptor blockade (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . The duration of therapy as well as dosing regimens 2. Idiotypic/antiidiotypic interactions differed between trials, making it difficult to draw definitive 3. Down-regulation of autoantibody production conclusions by combining the results of heterogeneous clinical 4. Direct effect on antibody-binding site on nerve, muscle, or neurotrials. Also, different preparations have been used, which may muscular junction contain varying amounts of monomeric IgG and F(ab')z frag-5. Solubilization of immune complexes ments. The nature of the preparation may have some ramifica-6. Possible action on natural killer or suppressor cells tion as to the efficacy of the drug, particularly as it pertains to the mechanism of action of IVIG in MG. These considerations Table 4 . Autoimmune basis of Guillain-Barri syndrome aside, it appears that about 65% of the treated patients have responded to a single course of high-dose IVIG (14) ( Table 2 ).
Antibodies to peripheral nerve antigens
In the single study that did not show any efficacy (22) 
T cells recognize nerve antigens
In most studies that reported a response, improvement appeared Activated, IL-2-positive T cells within 3 wk and may be noted as early as 2 d after the infusion.
Tissue immunopathology
Duration of the response was variable and seemed to be longer 
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into the source ofthe auW&pcs pmmt in MG. Oae can envision that such protectin mtihdh may be nrSpra8y maknt in subclinical arr of OgS. Other anti-peripheral aave a n t i i bave rlso been M m -with i n f l a m~~~t~r y clinically by the typical rash and pattern of weakness, PM is more ~C O U S and essentially is a diagnosis of exclusion requiring the need to search for drug systema, toxic, metabolic, (Table 9) . A beneficial response was noted within the first week after treatment in some cases, whereas in others it was not noted until after the second infusion, indicating a potential cumulative effect. One can only speculate on the mechanism of action of M G in these two diseases, inasmuch as no studies have been conducted to answer this question. In DM, an early mponse can certainly be due to solubilization of immune complexes that induce the complement de~osition in the microvascuhture. A rev& of the earliest ischemic lesion can "rescue" the muscle before infarction ensues. Other mechanisms listed in Table 3 could also explain the longterm benefit noted in these two studies, in which the duration of the response ranged from 1 to 24 mo.
CONCLUSIONS
We provide evidence supporting the conclusion that highdose M G is beneficial in autoimmunarelated neuromuscular disorders. With the exception of GBS, however, all of these studies are uncontrolled and preliminary. The mechanism of action of M G in these diseases remains largely unexplained. The direct effect on antibody-binding sites, which would be most operative in a disease like MG, has not really been demonstrated, and down-regulation of autoantibody production has been shown in only some patients. The possibility of idiotypic/antiidiotypic interaction is an attractive explanation for the beneficial effect in patients with MG, CIDP, and GBS.
The current role of M G as the first line therapy or adjunct therapy as a steroid-sparing agent in all of these conditions remains to be defined. Clearly, in GBS the evidence is overwhelmingthat M G compares favorably with PE. In the pediatric age group, in which PE may be impractical, M G should be the drug of choice in treating GBS and it should be c o n s i M in treating CIDP and MG. IVIG may prove to have a greater role as an adjunctive therapy to other immunosuppressive drugs, especially during exacerbations such as those seen with MG and CIDP. In PM and DM, M G appears also to be effective; however, only a double-blind, p l w n t r o l l e d trial, such as the one being conducted currently at the NM, will provide the definitive answer. HIV-infected subjects represent another group of patients who suffer from autoimmune neuromuscular diseases and who may benefit from M G therapy.
14. 
FLOOR DISCUSSION
Dr. Schwartz: Do you have any perception as to whether it is necessary to have the highdosage regimen for efficacy, or would some of the lowerdosage regimens be suitable in terms of this whole spectrum of autoimmune neumpathies? Have you gleaned anything that sqgests a trend or is there any evidence for one or the other? Dr. Soueidan: From reviewing the subject and from our limited clinical experience, I feel that the highdose IVIG is the one that is effective. Whether that is given over a 2 4 course as we give it or over a 4-or 5 4 course I & not think makes a difference.
Dr. Schw&tz: How about duration of effect? Dr. Soueidan*. The two pampmteinemic patients have been given infusions every 3 to 4 wk, and that is how we have been npanaging the patients in our study. That seems to be the expenence of most people. We treated one of the patients with weekly infusions of a quarter of the dose, but that did not seem to be as effective as a highdose infusion given once a month.
Dr. Schwartz: Have you had anyone or been aware of anyone in whom there has been a bcure" and no need for further treatment?
Dr. Soueidan: I am not aware of such patients. That m y be an important issue to study, and this is why I feel that M G may be an adjunctive treatment, at least in dosage order.
Dr. Levinson: Is any thought being given to trials using a combined approach with M G and plasmapheresis? That a p proach might be particuhrly useful in a disease like MG, which we know is mediated by autoantibodies. You have W e d about the interesting possibilities of antiidiotypic antibodies being involved and we know complement is involved, so plasmapheresis might have something to do with the antibodies and M G might have some effect on the antibodies, B cells, or complement deposition. Any thought being given to that kind of approach?
Dr. Soueidan: That goes back to one of the questions that was asked by Dr. Schwartz. If M G does turn out to have a disease coun&modulating effect, then a combination therapy might seem logical. At the present time that type of therapy is not available. I know Dr. Van Doom had treated one of his patients with both PE and M G and showed that that patient did well. Now whether that patient did better than on M G alone or on PE alone, he did not elaborate.
